Picture of Thor Medical ASA logo

TRMED Thor Medical ASA Share Price

0.000.00%
no flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapMomentum Trap

Momentum

Relative Strength (%)
1m-1.4%
3m-11.91%
6m+75.21%
1yr+120.75%
Volume Change (%)
10d/3m-79.77%
Price vs... (%)
52w High-50.85%
50d MA+5%
200d MA+26.59%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-11.22%
Return on Equity-13.86%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202531st Dec 2026
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2025 / 2026

Blurred out image of Thor Medical ASA EPS forecast chart

Profile Summary

Thor Medical ASA, formerly Nordic Nanovector ASA, is a Norway-based biopharmaceutical company. The Company is a producer and supplier of alpha-particle emitters for cancer therapy. The production process is based on separation of natural occurring radioactive decay products from thorium. The Company is utilizing alpha-emitters in radiotherapy and cancer treatments using Pb-212, which can be produced from naturally occurring isotope Thorium-232 and Lead-212. The Company has developed a proprietary technology for the manufacturing of radionuclides, primarily alpha-particle emitters from natural resources. The high energy deposition and the short range of alpha particles make it possible to eradicate cancer cells while minimizing damage to nearby healthy cells

Directors

Last Annual
December 31st, 2024
Last Interim
December 31st, 2024
Incorporated
July 7th, 2009
Public Since
July 7th, 2014
No. of Shareholders
14,060
No. of Employees
9
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
no flag iconOslo Stock Exchange
Shares in Issue
280,492,395

TRMED Share Price Performance

Upcoming Events for TRMED

Similar to TRMED

Picture of Arcticzymes Technologies ASA logo

Arcticzymes Technologies ASA

no flag iconOslo Stock Exchange

Picture of Bergenbio ASA logo

Bergenbio ASA

no flag iconOslo Stock Exchange

Picture of Circio Holding ASA logo

Circio Holding ASA

no flag iconOslo Stock Exchange

Picture of Exact Therapeutics AS logo

Exact Therapeutics AS

no flag iconOslo Stock Exchange

Picture of Lifecare ASA logo

Lifecare ASA

no flag iconOslo Stock Exchange

FAQ